Yuqi Huang

Yuqi Huang

Auto-generated profile, based on publicly available information

Yuqi Huang

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
BDBaijun Dong
Baijun Dong
JXJunyu Xu
Junyu Xu
YHYuqi Huang
Yuqi Huang
JGJiacheng Guo
Jiacheng Guo
QDQun Dong
Qun Dong
JQJun Qin
Jun Qin

1 May 2023 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZWZiruoyu Wang
Ziruoyu Wang
YLYanan Li
Yanan Li
WZWensi Zhao
Wensi Zhao
SJShuai Jiang
Shuai Jiang
YHYuqi Huang
Yuqi Huang
YDYongjun Dang
Yongjun Dang
Prostate cancer (PCa) is the second most prevalent malignancy in males across the world. A greater knowledge of the relationship between protein abundance and drug responses would benefit precision treatment for PCa. Herein, we establish 35 Chinese PCa primary cell models to capture specific characteristics among PCa patients, including gene mutations, mRNA/protein/surface protein distributions, and pharmaceutical responses. The multi-omics analyses identify Anterior Gradient 2 (AGR2) as a pre-operative prognostic biomarker in PCa. Through the drug library screening, we describe crizotinib as a selective compound for malignant PCa primary cells. We further perform the pharmacoproteome analysis and identify 14,372 significant protein-drug correlations. Surprisingly, the diminished AGR2 enhances the inhibition activity of crizotinib via ALK/c-MET-AKT axis activation which is validated by PC3 and xenograft model. Our integrated multi-omics approach yields a comprehensive understanding of PCa biomarkers and pharmacological responses, allowing for more precise diagnosis and therapies.

3 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LTLianmei Tan
Lianmei Tan
TYTao Yin
Tao Yin
HXHandan Xiang
Handan Xiang
LWLiuyang Wang
Liuyang Wang
PMPoorva Mudgal
Poorva Mudgal
XWXiao-Fan Wang
Xiao-Fan Wang
Immunotherapy successfully complements traditional cancer treatment. However, primary and acquired resistance might limit efficacy. Reduced antigen presentation by MHC-I has been identified as potential resistance factor. Here we show that the epigenetic regulator ubiquitin-like with PHD and ring finger domains 1 (UHRF1), exhibits altered expression and aberrant cytosolic localization in cancerous tissues, where it promotes MHC-I ubiquitination and degradation. Cytoplasmic translocation of UHRF1 is induced by its phosphorylation on a specific serine in response to signals provided by factors present in the tumor microenvironment (TME), such as TGF-β, enabling UHRF1 to bind MHC-I. Downregulation of MHC-I results in suppression of the antigen presentation pathway to establish an immune hostile TME. UHRF1 inactivation by genetic deletion synergizes with immune checkpoint blockade (ICB) treatment and induces an anti-tumour memory response by evoking low-affinity T cells. Our study adds to the understanding of UHRF1 in cancer immune evasion and provides a potential target to synergize with immunotherapy and overcome immunotherapeutic resistance.


31 August 2023 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
ZLZhiwei Liu
Zhiwei Liu
SJShangwen Jiang
Shangwen Jiang
BHBingbing Hao
Bingbing Hao
SXShuyu Xie
Shuyu Xie
YLYingluo Liu
Yingluo Liu
JXJunyu Xu
Junyu Xu
Pharmacological perturbation studies based on protein-level signatures are fundamental for drug discovery. In the present study, we used a mass spectrometry (MS)-based proteomic platform to profile the whole proteome of the breast cancer MCF7 cell line under stress induced by 78 bioactive compounds. The integrated analysis of perturbed signal abundance revealed the connectivity between phenotypic behaviors and molecular features in cancer cells. Our data showed functional relevance in exploring the novel pharmacological activity of phenolic xanthohumol, as well as the noncanonical targets of clinically approved tamoxifen, lovastatin, and their derivatives. Furthermore, the rational design of synergistic inhibition using a combination of histone methyltransferase and topoisomerase was identified based on their complementary drug fingerprints. This study provides rich resources for the proteomic landscape of drug responses for precision therapeutic medicine.